Oncolys BioPharma, Inc. (JP:4588) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Oncolys BioPharma Inc. saw a significant decline in net sales, dropping 50.2% to 31 million yen for the first nine months of 2024 compared to the same period in 2023. Despite a challenging financial performance, the company improved its equity ratio to 81.5%, up from 71.5% at the end of 2023. Notably, the company did not provide a forecast for the fiscal year ending December 2024 due to uncertainties in making reasonable estimates.
For further insights into JP:4588 stock, check out TipRanks’ Stock Analysis page.